Forms and functions of p53 - PubMed

Affiliations

• PMID: 7948949

Review

Forms and functions of p53

J Milner. Semin Cancer Biol. 1994 Jun.

Abstract

There is evidence that wild-type p53 can both promote and suppress cell proliferation and these opposing functions correlate with alternative conformations of the p53 protein. In the light of more recent evidence I now propose that wild-type p53 can adopt at least three different forms, each of which correlates with a defined function in cell growth control. The three forms are most simply defined by reactivity with two monoclonal antibodies, PAb421 and PAb1620. One form (421 degrees/1620+) suppresses cell growth and maintains quiescence, and a second form (421+/1620 degrees) activates and promotes cell proliferation. The third form (421+/1620+) acts as a differential sensor for incoming positive and negative growth regulatory signals and can be converted either to the suppressor or to the promoter form for cell growth. Regulation of p53 tertiary structure involves redox modulation and phosphorylation, and offers a novel rationale for anti-cancer therapy.

Similar articles

• The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.

  Hansen S, Lane DP, Midgley CA. Hansen S, et al. J Mol Biol. 1998 Jan 30;275(4):575-88. doi: 10.1006/jmbi.1997.1507. J Mol Biol. 1998. PMID: 9466932

• Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135.

  Milner J, Medcalf EA. Milner J, et al. J Mol Biol. 1990 Dec 5;216(3):481-4. doi: 10.1016/0022-2836(90)90371-R. J Mol Biol. 1990. PMID: 2258922

• Molecular "rehabilitation" by rational drug targeting: the challenge of P53 in cancer treatment.

  Tzatsos A, Papavassiliou AG. Tzatsos A, et al. Anticancer Res. 1999 Sep-Oct;19(5B):4353-6. Anticancer Res. 1999. PMID: 10628400 Review.

• Gain-of-function mutations in the tumor suppressor gene p53.

  van Oijen MG, Slootweg PJ. van Oijen MG, et al. Clin Cancer Res. 2000 Jun;6(6):2138-45. Clin Cancer Res. 2000. PMID: 10873062 Review.

Cited by

• Temperature-sensitive ovarian carcinoma cell line (OvBH-1).

  Bar JK, Harlozinska A, Kartarius S, Montenarh M, Wyrodek E, Parkitna JM, Kochman M, Ozyhar A. Bar JK, et al. Jpn J Cancer Res. 2002 Sep;93(9):976-85. doi: 10.1111/j.1349-7006.2002.tb02473.x. Jpn J Cancer Res. 2002. PMID: 12359050 Free PMC article.

• p53 status of newly established acute myeloid leukaemia cell lines.

  Zheng A, Castren K, Säily M, Savolainen ER, Koistinen P, Vähäkangas K. Zheng A, et al. Br J Cancer. 1999 Feb;79(3-4):407-15. doi: 10.1038/sj.bjc.6690064. Br J Cancer. 1999. PMID: 10027306 Free PMC article.

• Role of p53 suppression in the pathogenesis of hepatocellular carcinoma.

  Choudhary HB, Mandlik SK, Mandlik DS. Choudhary HB, et al. World J Gastrointest Pathophysiol. 2023 Jun 1;14(3):46-70. doi: 10.4291/wjgp.v14.i3.46. World J Gastrointest Pathophysiol. 2023. PMID: 37304923 Free PMC article. Review.

• MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?

  Azer SA. Azer SA. J Clin Med. 2018 Mar 27;7(4):64. doi: 10.3390/jcm7040064. J Clin Med. 2018. PMID: 29584707 Free PMC article. Review.

• Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

  Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Blagosklonny MV, et al. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8379-83. doi: 10.1073/pnas.93.16.8379. Proc Natl Acad Sci U S A. 1996. PMID: 8710879 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal